Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual Meeting

REFERENCES

1. 1.↵
   1. Armstrong AW,
   2. Reddy SB,
   3. Garg A

   . Novel approach to utilizing electronic health records for dermatologic research: developing a multi-institutional federated data network for clinical and translational research in psoriasis and psoriatic arthritis. Dermatol Online J 2012;18:2.

   OpenUrlPubMed
2. 2.↵
   1. Ananthakrishnan AN,
   2. Cai T,
   3. Savova G,
   4. Cheng SC,
   5. Chen P,
   6. Perez RG,
   7. et al.

   Improving case definition of Crohn’s disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis 2013;19:1411–20.

   OpenUrlCrossRefPubMed
3. 3.↵
   EMA Dermatology [Internet. Accessed March 26, 2014.] Available from: www.modmed.com/dermatology-features
4. 4.↵
   Epic. [Internet. Accessed March 26, 2014.] Available from: www.epic.com/software-index.php
5. 5.↵
   Cerner acute care electronic medical record. [Internet. Accessed March 26, 2014.] Available from: www.cerner.com/solutions/Hospitals_and_Health_Systems/Acute_Care_EMR/
6. 6.↵
   1. Weinstock MA,
   2. Bingham SF,
   3. Digiovanna JJ,
   4. Rizzo AE,
   5. Marcolivio K,
   6. Hall R,
   7. et al.

   Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012;132:1583–90.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Asgari MM,
   2. Wu JJ,
   3. Gelfand JM,
   4. Salman C,
   5. Curtis JR,
   6. Harrold LR,
   7. et al.

   Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. Pharmacoepidemiol Drug Saf 2013;22:842–9.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Seminara NM,
   2. Abuabara K,
   3. Shin DB,
   4. Langan SM,
   5. Kimmel SE,
   6. Margolis D,
   7. et al.

   Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol 2011;164:602–9.

   OpenUrlPubMed
9. 9.↵
   1. Gelfand JM,
   2. Weinstein R,
   3. Porter SB,
   4. Neimann AL,
   5. Berlin JA,
   6. Margolis DJ

   . Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:1537–41.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Ogdie A,
    2. Langan S,
    3. Love T,
    4. Haynes K,
    5. Shin D,
    6. Seminara N,
    7. et al.

    Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology 2013;52:568–75.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Wan J,
    2. Wang S,
    3. Haynes K,
    4. Denburg MR,
    5. Shin DB,
    6. Gelfand JM

    . Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ 2013;347:f5961.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Yeung H,
    2. Takeshita J,
    3. Mehta NN,
    4. Kimmel SE,
    5. Ogdie A,
    6. Margolis DJ,
    7. et al.

    Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013;149:1173–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Psonet

    . European surveillance network to monitor the long term effectiveness and safety of systemic agents in the treatment of psoriasis [Internet. Accessed March 26, 2014.] Available from: www.psonet.eu/cms/
14. 14.↵
    1. Liu Y,
    2. Wu EQ,
    3. Bensimon AG,
    4. Fan CP,
    5. Bao Y,
    6. Ganguli A,
    7. et al.

    Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012;29:620–34.

    OpenUrlCrossRefPubMed
15. 15.↵
    The German Psoriasis Registry (PsoBest) [Internet. Accessed March 26, 2014.]. Available from: www.psobest.de/
16. 16.↵
    Australasian Psoriasis Registry (APR) [Internet. Accessed March 26, 2014.]. Available from: https://psoriasis.asn.au/
17. 17.↵
    1. Gelfand JM,
    2. Wan J,
    3. Callis Duffin K,
    4. Krueger GG,
    5. Kalb RE,
    6. Weisman JD,
    7. et al.

    Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol 2012;148:487–94.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Yeung H,
    2. Wan J,
    3. Van Voorhees AS,
    4. Callis Duffin K,
    5. Krueger GG,
    6. Kalb RE,
    7. et al.

    Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013;68:64–72.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Callis Duffin K,
    2. Yeung H,
    3. Takeshita J,
    4. Krueger GG,
    5. Robertson AD,
    6. Troxel AB,
    7. et al.

    Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol 2014;170:672–80.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Armstrong AW,
    2. Robertson AD,
    3. Wu J,
    4. Schupp C,
    5. Lebwohl MG

    . Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003–2011. JAMA Dermatol 2013;149:1180–5.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Bhutani T,
    2. Wong JW,
    3. Bebo BF,
    4. Armstrong AW

    . Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol 2013;149:717–21.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Armstrong AW,
    2. Schupp C,
    3. Wu J,
    4. Bebo B

    . Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One 2012;7:e52935.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Gladman DD,
    2. Chandran V

    . Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future? Curr Rheumatol Rep 2011;13:346–52.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Papp KA,
    2. Strober B,
    3. Augustin M,
    4. Calabro S,
    5. Londhe A,
    6. Chevrier M

    . PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012;11:1210–7.

    OpenUrlPubMed
25. 25.↵
    British Association of Dermatologists Biologic Interventions Registry (BADBIR) [Internet. Accessed March 26, 2014.]. Available from: www.badbir.org/index.aspx.
26. 26.↵
    Consortium of Rheumatology Researchers of North America (CORRONA). [Internet. Accessed March 26, 2014.] Available from: http://corrona.com/p/index.html.
27. 27.↵
    1. Dreiher J,
    2. Freud T,
    3. Cohen AD

    . Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract 2013;2013:580404.

    OpenUrlPubMed
28. 28.↵
    1. Ahlehoff O,
    2. Skov L,
    3. Gislason G,
    4. Lindhardsen J,
    5. Kristensen SL,
    6. Iversen L,
    7. et al.

    Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013;273:197–204.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Tsai TF,
    2. Wang TS,
    3. Hung ST,
    4. Tsai PI,
    5. Schenkel B,
    6. Zhang M,
    7. et al.

    Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011;63:40–6.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Centers for Medicare and Medicaid Services

    . [Serial on the Internet. Accessed March 26, 2014.] Available from: www.cms.gov/.
31. 31.↵
    1. Armstrong AW,
    2. Idriss N,
    3. Bergman H

    . Physician workforce for acne care in the United States, 2003 through 2005. Arch Dermatol 2009;145:1195–6.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Johnson JA,
    2. Ma C,
    3. Kanada KN,
    4. Armstrong AW

    . Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. J Eur Acad Dermatol Venereol 2014r;28:327–32.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Ma C,
    2. Schupp CW,
    3. Armstrong EJ,
    4. Armstrong AW

    . Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES). J Eur Acad Dermatol Venereol 2013 Aug 1 (E-pub ahead of print).
34. 34.↵
    1. Armstrong AW,
    2. Follansbee MR,
    3. Harskamp CT,
    4. Schupp CW

    . Psoriasis and Sexual Behavior in U.S. Women: an epidemiologic analysis using the National Health and Nutrition Examination Survey (NHANES). J Sex Med 2013;10:326–32.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Armstrong AW,
    2. Harskamp CT,
    3. Schupp CW

    . Psoriasis and Sexual Behavior in Men: examination of the National Health and Nutrition Examination Survey (NHANES) in the United States. J Sex Med 2014;11:394–400.

    OpenUrlCrossRefPubMed
36. 36.↵
    Clinical Practice Research Datalink (CPRD) [Internet. Accessed March 26, 2014.]. Available from: www.cprd.com/intro.asp
37. 37.↵
    Thomson Reuters [Internet. Accessed March 26, 2014.]. Available from: https://marketscan.truvenhealth.com/marketscanportal
38. 38.↵
    1. Parsi K,
    2. Chambers CJ,
    3. Armstrong AW

    . Cost-effectiveness analysis of a patient-centered care model for management of psoriasis. J Am Acad Dermatol 2012;66:563–70.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Armstrong AW,
    2. Harskamp CT,
    3. Cheeney S,
    4. Schupp CW

    . Crowdsourcing in eczema research: a novel method of data collection. J Drugs Dermatol 2012;11:1153–5.

    OpenUrlPubMed
40. 40.↵
    1. Armstrong AW,
    2. Harskamp CT,
    3. Cheeney S,
    4. Schupp CW

    . Crowdsourcing for research data collection in rosacea. Dermatol Online J 2012;18:15.

    OpenUrlPubMed
41. 41.↵
    1. Armstrong AW,
    2. Harskamp CT,
    3. Cheeney S,
    4. Wu J,
    5. Schupp CW

    . Power of crowdsourcing: novel methods of data collection in psoriasis and psoriatic arthritis. J Am Acad Dermatol 2012;67:1273–81e9.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Armstrong AW,
    2. Wu J,
    3. Harskamp CT,
    4. Cheeney S,
    5. Schupp CW

    . Crowdsourcing for data collection: a pilot study comparing patient-reported experiences and clinical trial data for the treatment of seborrheic dermatitis. Skin Res Technol 2013;19:55–7.

    OpenUrlCrossRefPubMed